









Global Pharmaceutical Industry in the 1990s

- · Rapid industry growth
 - · Concentrated markets in North America, Japan and Europe
 - Top 50 companies made up 60-75% of total sales
- · Expensive and time consuming industry
- · 20 year patent protection
- · Increasing health care costs



Company History

- · Founded in 1876 by Eli Lilly
- · Started as a family business
- · Generated \$11,000 in sales its first year
- · 1905: sales increased to over \$1 million
- · 1917: largest capsule production factory in the world
- 1952: company went public
- · Mid 1980's Lilly starts global expansion
- 1992: world leader in manufacturing antibiotics, insulin and diabetic care
- · Expansion options


Indian Pharmaceutical Industry Progression

RANBAXY

- Growing population over 800 million
- Switch from importing to generic drug production
 - · DPCO and 1970 Patents Act
- · Ranbaxy Laboratories
 - Start up in 1960 as family business
 - · Exported to 47 countries
 - · Capital costs significantly lower than the U.S.
 - · Largest generic and bulk drug producers in India
 - · Positive brand recognition in India

Company History

- Founded in 1876 by Eli Lilly
- Started as a family business
- Generated \$11,000 in sales its first year
- 1905: sales increased to over \$1 million
- 1917: largest capsule production factory in the world
- 1952: company went public
- Mid 1980's Lilly starts global expansion
- 1992: world leader in manufacturing antibiotics, insulin and diabetic care
- Expansion options



Global Pharmaceutical Industry in the 1990s

- Rapid industry growth
 - · Concentrated markets in North America, Japan and Europe
 - Top 50 companies made up 60-75% of total sales
- Expensive and time consuming industry
- 20 year patent protection
- Increasing health care costs



Indian Pharmaceutical Industry Progression

- Growing population over 800 million
- Switch from importing to generic drug production
 - DPCO and 1970 Patents Act
- Ranbaxy Laboratories
 - Start up in 1960 as family business
 - Exported to 47 countries
 - Capital costs significantly lower than the U.S.
 - · Largest generic and bulk drug producers in India
 - Positive brand recognition in India

